Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Journal of the International AIDS Society|October 15, 2009
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral DrugsDan Turner, Bluma Brenner, Daniela Moisi, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2006
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsMichel Ntemgwa, Bluma G Brenner, Maureen Oliveira, et al.
The Journal of Antimicrobial Chemotherapy|July 14, 2011
Transmission dynamics of the M184V drug resistance mutation in primary HIV infectionMark A Wainberg, Daniela Moisi, Maureen Oliveira, et al.
Antimicrobial Agents and Chemotherapy|June 19, 2002
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1Karidia Diallo, Maureen Oliveira, Daniela Moisi, et al.
AIDS Research and Human Retroviruses|July 3, 2008
Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfectionMichel Ntemgwa, M John Gill, Bluma G Brenner, et al.
Antiviral Chemistry & Chemotherapy|November 13, 2004
Variability in the PR and RT genes of HIV-1 isolated from recently infected subjectsDan Turner, Ariel Roldan, Bluma Brenner, et al.
Virologie (Montrouge, France)|August 25, 2021
[L'usage de papier buvard de type « FTATM Classic » pour la détection et le génotypage du VIH chez des hommes ayant des relations sexuelles avec d'autres hommes à Montréal (Québec, Canada)]Frédéric Ohnona, Daniela Moisi, Ilinca Ibanescu, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2004
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue cultureMarco Petrella, Maureen Oliveira, Daniela Moisi, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutationsMaureen Oliveira, Daniela Moisi, Bonnie Spira, et al.
Journal of the International AIDS Society|November 15, 2014
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group MAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
Pageof 7